Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

ComBac-Africa Combating Multidrug-Resistant Gram-Negative Bacteria in Africa through Diagnostic and Antimicrobial Stewardship

Coordinator
Universitat Des Saarlandes, Germany
Runs
1 May 2025 to 30 April 2029
Status
Running
EU funding
€5.9m
Total cost
€5.9m
Partners
12 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101190791

What the project is doing

In the project's own words, from its summary on CORDIS.

Antimicrobial resistance is a major global health threat for humans, animals and the environment, with the highest mortality and morbidity rates in sub-Saharan Africa (SSA). The World Health Organization prioritised several carbapenem- and third-generation cephalosporin-resistant Gram-negative bacteria such as Enterobacterales as the most critical pathogens with only very limited treatment options. Bacteraemia, sepsis and other severe infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) give rise to excess mortality.

Yet, the causative pathogens are rarely identified in patients in SSA due to a lack of microbiological diagnostics. Carbapenems and the new antibiotics ceftazidime-avibactam, cefiderocol and aztreonam-avibactam are active against different MDR GNB and could significantly reduce morbidity and mortality, but they are not widely available in SSA.The ComBac-Africa consortium has the overall goal to improve the management of severe infections due to MDR GNB in Côte d’Ivoire, Guinea-Bissau and Nigeria through the establishment of a needs-adapted diagnostic and antimicrobial stewardship (AMS) programme that provides equitable access to these novel antibiotics for targeted treatment.

This will be achieved through (1) provision of high-quality and accurate microbiological diagnostics for prompt and correct identification of causative agents in bacteraemia and other severe infections; (2) a comprehensive One Health assessment of the epidemiology of GNB in humans, animal and environmental specimens; (3) tailored AMS initiatives, including early outbreak detection and infection prevention measures, to optimise the use of novel antimicrobials; (4) development of clinical algorithms for targeted diagnosis and treatment of infections due to MDR GNB; and (5) establishment of sustainable and affordable access to these antibiotics in SSA.

A clinical trial will assess and quantify the impact of this multi-pronged intervention on patient outcome.

Topics

Who is involved

OrganisationCityCountryRole
Universitat Des SaarlandesSaarbruckenGermanyCoordinator
Fondation Pour Un Centre Suisse De Recherches Scientifiques En Cote D'ivoireAbidjanSwitzerlandAssociatedpartner
GARDP FoundationGeneveSwitzerlandAssociatedpartner
Schweizerisches Tropen Und Public Health InstitutAllschwilSwitzerlandAssociatedpartner
Institut Pasteur De Cote D'ivoireAbidjanCIParticipant
Linq Management GmbHBerlinGermanyParticipant
Ministerio Da Saude PublicaBissauGWParticipant
Centre for Malaria and Other Tropical Diseases Care, IlorinIlorinNGParticipant
Joseph Sarwuan Tarka University MakurdiMakurdiNGParticipant
Obafemi Awolowo UniversityIle IfeNGParticipant
Instituto Piaget Coop Para O Desenvimento Humano Integral Ecologico CrlCanelas Vila Nova De GaiaPortugalParticipant
Gardp Africa NpcWestern Cape Cape TownSouth AfricaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI